Current Report Filing (8-k)
02 October 2018 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 1, 2018
DERMIRA, INC.
(Exact
Name of the Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
001-36668
|
|
27-3267680
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
275 Middlefield Road, Suite 150
Menlo Park, California
|
|
94025
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(650)
421-7200
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On October 1, 2018, Dermira, Inc. (the Company) presented an overview of the Company to certain investors and analysts at the
Cantor 2018 Global Healthcare Conference (the Presentation). A copy of the Presentation, which will be available on the Companys website at www.dermira.com under the tab Investors & Media, is attached hereto as
Exhibit 99.1, and is incorporated herein by reference.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any
registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly stated by specific reference in such filing. The information contained in, or that can be accessed through
the Companys website, is not a part of this filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Dated: October 1, 2018
|
|
|
|
DERMIRA, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Andrew L. Guggenhime
|
|
|
|
|
Name:
|
|
Andrew L. Guggenhime
|
|
|
|
|
Title:
|
|
Chief Financial Officer
|
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024